A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06563505
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06563375
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06561087
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06561074
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06548789
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Clinical and Molecular Features of Oral Premalignancy and Oral Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1000
- Registration Number
- NCT06550050
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06549413
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT06548776
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06548412
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
ACT-Together (Acting on Cancer Testing-Together)
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06549153
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath